doc, agree from my quick look it directs FDA to issue regulations and guidance yada yada yada, within 36 months of passage yada yada yada. They can write whatever guidance they want.
monarch, I have scanned the Bill, it's 350 pages, and not sure there is anything in it that would give MDXG any near term relief from the BLA process. But will look more closely when I have a chance
doc, you hit the nail on the head. We are seeing the "hot money" leave yesterday and today, "hot money" being momentum players. Don't let the door hit you on the way out boys. One thing I do not agree with you is that we are not in the high growth realm, depending on how you define high growth. Analysts expect 50% growth next year or two and then 25%+ beyond. That ignores new products of course. In my book, that is high growth, maybe not hyper growth like 100% but high growth. And earth, no delay on BLA. BLA HAS to proceed. Not waiting to her whether BLA is going to be required, just waiting to hear whether company is free to market it and sell it during the BLA process.
Very excited about collafix..I see this product at some point in producing as much revenue as EpiFix is now. Could take company to $500MM in revenue by 2018
shuching4, do you even follow this company at all? The slowing of sales makes no sense of all? Gee, maybe he got it by listening to the conference calls and reading their press releases where management has told everyone that sales would be slower going forward than in the past? You think that is a possibility? The company has grown revenue at a 100% clip, that is not happening next year. They will do close to $200 million revenue this year. Consensus next year is about 250 million. (I think they will do more). It's easy for start ups to grow revenue 100% per year when they are starting at zero but once they get to a certain size you don't keep growing at a 100% clip. Apple used to grow 100% a year but they don't anymore
EARTH, it wouldn't matter if it wasn't a quiet period. A company isn't going to respond to an analyst reducing his rating from a strong buy to a buy or even if he downgraded to a hold. Now, if an analyst put something in a note that was just blatantly false information, that is another matter
April 28, 2015 earnings call: "the real thing is going to ruin short day and have done that before, is when the press release comes out and says, company X has been acquired by company Y."
People....you need to understand something. Dueling? Many banks don't even have a rating called "strong buy"...they just have buy, market perform and underperform. Needham happens to have the strong buy rating which is reserved for stocks where the price target is WELL above current price. it's not like Matson lowered to market perform. he is still at a BUY rec. A BUY rec isn't negative. he has the same rating on the stock as Bruce at Lake Steet!
The usual reason. Valuation and they think the lack of a pre-announcement means an in line quarter.
We are downgrading MDXG to Buy from Strong Buy given
more difficult comps for the remainder of the year, our belief that upside to consensus
may be more limited, and valuation. We note that we still expect MDXG to maintain
growth above its small-cap growth peers and believe that its leadership position in the
amniotic tissue market makes it an attractive asset. We maintain our estimates and our
$15 price target.
We received the strongest buy signal possible this morning at around 10:30. No, I am not talking about technical analysis or some fancy chart but Candycez appeared about 10:30 with his "sell sell sell" when the stock was about $12.50. Based on Candy's 100% track record of being wrong and the stock going higher when he crawls out of his s___hole and says "sell sell sell" or predicts something bad is coming, a major buy signal was triggered at $12.50 which is why the stock is moving now and at $12.81 as I type. Should go quite a bit higher from Candy's sell advice.
Fairly new to the stock. Long time holder of MDXG since sub $1. Gorlin family seems to strike Gold on everything they touch so my money is on our CEO here.
Interesting mention in the Miami Herald today. Link on stock twits
Knee pain: Avenues to explore for those with arthritis
Once a method can be developed to secure the stem cells to the arthritic areas of the knee and trigger the cells to form cartilage then this will potentially revolutionize arthritis treatment. Amniofix is an amniotic compound injected into the knee just being studied for arthitis treament.
Dr. Harlan Selesnick is team physician of the Miami Heat and director of Miami Sports Medicine Fellowship, Doctors Hospital.
earth, I have felt the same way about why they have pre released the last 5 quarters, often to support the stock. You may get a pop on pre release but then nothing when earnings are released
bu3800. I have worked in the M&A area for a long time. It's hard to come up with a premium because it can vary wildly depending on where a stock is priced. That's why you see people whine so much often times and see the slimebag law firms come out when a company is bought and the premium isn't very much. Let's take a hypothetical. Let's say next spring MDXG is trading in the 13s and est revenue in 2016 is 240MM. That's a 6 multiple. Would not surprise me to see a 40% premium or $18. But, let's say the stock is trading at a 8 multiple or around $18. You won't see a 40% premium if it is at that price because that would equate to a 12 multiple, way too high. So to a large extent, a stock's price at the time it is sold dictates how high the premium will be. For instance, once in a while you see a company sold fairly close to the current stock price but maybe there was a leak and the stock ran up big in the days/weeks leading up to the announcement. That doesn't mean that the company sold too low, just that the stock price already reflected the premium at the time of the announcement.